At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer
AstraZeneca, which already has a strong presence in lung cancer, is poised to deepen its reach in the disease with ...
AstraZeneca, which already has a strong presence in lung cancer, is poised to deepen its reach in the disease with ...
An Insmed drug developed for a serious chronic lung disorder with no FDA-approved therapies handily beat a placebo in a ...
Saudi Arabia’s 88-year-old King Salman has been diagnosed with a lung infection and is currently receiving antibiotic treatment after experiencing ...
© Reuters. Tuesday, Citi initiated coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $30.00. ...
Copyright © 2024 EuroAsia24 News.
EuroAsia24 News is not responsible for the content of external sites.